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Abstract
Background: Pharmacokinetic studies with XM17 (Ovaleap®), a recombinant human follicle-stimulating hormone
(r-hFSH, follitropin alfa), have demonstrated good safety and tolerability in healthy women whose endogenous
FSH levels were down-regulated with a long agonist protocol. In these studies, Ovaleap® pharmacokinetics were
dose-proportional and bioequivalent to the reference follitropin alfa product (Gonal-f®). The objective of the present
study is to determine whether Ovaleap® is equivalent to Gonal-f® with respect to the number of oocytes retrieved in
infertile but ovulatory women undergoing assisted reproductive technology (ART) therapy.
Methods: This multinational, multicenter, randomized (1:1), active-controlled, assessor-blind, comparative study
included infertile normally gonadotrophic women 18 to 37 years old with a body mass index of 18 to 29 kg/m2
and regular menstrual cycles of 21 to 35 days undergoing ART therapy. During a 5-day fixed-dose phase, women
received 150 IU/day of Ovaleap® (n = 153) or Gonal-f® (n = 146), followed by an up to 15-day dose-adaptation
phase during which doses could be adjusted every 3 to 5 days, up to a maximum of 450 IU/day. Ovaleap® was to
be deemed equivalent to Gonal-f® if the two-sided 0.95 confidence interval (CI) for the difference in the number
of oocytes retrieved fell within the equivalence range of ±3 oocytes.
Results: Similar numbers of oocytes were retrieved in the 2 treatment groups. The mean ± SD number of oocytes
retrieved was 12.2 ± 6.7 in the Ovaleap® group and 12.1 ± 6.7 in the Gonal-f® group (intent-to-treat [ITT] population).
Regression analysis estimated a mean difference of 0.03 oocytes between the treatment groups (95 % CI: −0.76-0.82),
which was well within the prespecified equivalence range of ±3 oocytes. Ovaleap® and Gonal-f® showed favorable and
comparable safety profiles, with no unexpected safety findings.
Conclusions: Ovaleap® has shown the same efficacy and safety as Gonal-f® for stimulation of follicular development in
infertile women (up to 37 years of age) who are undergoing ART therapy.
Trial Registration: EudraCT: 2009-017674-20. Current controlled trials: ISRCTN74772901. Date of trial registration: 19
March 2010.
Keywords: Ovaleap, Follitropin alfa, Gonal-f, Infertility, Assisted reproductive technology (ART)
* Correspondence: thomas_strowitzki@med.uni-heidelberg.de
1Department of Gynecological Endocrinology and Reproductive Medicine,
University of Heidelberg, Im Neuenheimer Feld 440, 69120 Heidelberg,
Germany
Full list of author information is available at the end of the article
© 2016 Strowitzki et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Strowitzki et al. Reproductive Biology and Endocrinology  (2016) 14:1 
DOI 10.1186/s12958-015-0135-8
Background
Exogenous gonadotropins, including follicle-stimulating
hormone (FSH), are often used to treat infertility by in-
ducing ovulation or controlled ovarian stimulation in
the context of assisted reproductive technology (ART).
Available FSH products include urinary-derived human
menopausal gonadotropin (hMG), purified urinary FSH,
highly purified urinary FSH, and recombinant human
FSH (r-hFSH) [1, 2].
r-hFSH was developed, in part, to increase FSH pro-
duction independent of urine collection, to ensure
greater availability, and to reduce the variability due to
the inherent inconsistency of the starting materials
[3]. r-hFSH also offers the potential additional benefit
of a reduced risk of immunological reactions due to
impurities [3, 4].
Marketed r-hFSH products available in Europe include
follitropin alfa (Gonal-f® and Bemfola®), follitropin beta
(Puregon®), and a long-acting FSH, corifollitropin alfa
(Elonva®).
Ovaleap® (follitropin alfa) is an r-hFSH manufactured
in Chinese hamster ovary (CHO) cells. It was developed
as a biosimilar to Gonal-f® as recommended by the
European Union in their guidelines for the clinical de-
velopment of biological medicinal products that con-
tain r-hFSH [5], and was approved by the European
Medicines Association as a biosimilar in 2013. Biosimi-
lar formulations represent products with demonstrated
similarity in physicochemical characteristics, efficacy,
and safety to an approved product in comprehensive
comparability studies [6]. Ovaleap® is primarily intended
for use in controlled ovarian stimulation in women under-
going ART procedures and for the treatment of anovula-
tion. It is also indicated to treat women with severe FSH
or luteinizing hormone deficiency and to stimulate sperm-
atogenesis in men. The amino acid sequence of Ovaleap®
is identical to that of the follitropins currently registered
in Europe, and its tertiary structure is also similar.
Two pharmacokinetic studies of Ovaleap® in healthy fe-
male subjects have provided preliminary evidence of its
potential utility. In a dose-response study, Ovaleap® admin-
istered in single subcutaneous (SC) doses up to 300 IU to
healthy pituitary down-regulated women (N = 40), demon-
strated dose-proportionality and was well tolerated [7, 8].
A second study demonstrated the bioequivalence of
300 IU of Ovaleap® and 300 IU of Gonal-f® as assessed
by peak plasma concentration (Cmax) and area under
the concentration vs time curve (AUC0-t) [9]. In both of
these pharmacokinetic studies, Ovaleap® was safe and
well tolerated.
The primary objective of this phase 3 patient-study was
to evaluate the clinical efficacy of Ovaleap® compared with
Gonal-f® in terms of the number of oocytes retrieved and
safety in infertile ovulatory women undergoing ART
therapy. The number of oocytes retrieved is the primary
endpoint recommended by the European Medicines
Agency for studies evaluating the clinical comparability
of Gonal-f® and the similar formulation [5]. Moreover,
historical data have demonstrated the strong associ-
ation between the number of retrieved eggs and live
birth rates [10]. Other efficacy parameters were also
compared, as were safety and tolerability.
Methods
This was a multinational, randomized, active-controlled, as-
sessor (ie, investigator and embryologist)-blinded, parallel-
group patient study conducted between March 2010 and
July 2011 in 20 centers in 5 countries (Belgium, Czech
Republic, Germany, Hungary, and Poland). The study
protocol and informed consent documents were ap-
proved by the relevant independent ethics committees.
The study was conducted in accordance with the Good
Clinical Practice Consolidated Guideline, according to
the International Conference on Harmonisation and
the Declaration of Helsinki (1996).
Participants
Women aged 18 to 37 years were eligible for inclusion
in the study if they were infertile but otherwise healthy,
were normally gonadotrophic, had 2 confirmed normal
ovaries, and were undergoing controlled ovarian stimu-
lation with ART therapy. Women also must have had
regular menstrual cycles of 21 to 35 days; body mass
index (BMI) between 18 and 29 kg/m2; and basal FSH,
estradiol, prolactin, and thyroid-stimulating hormone
concentrations in the normal range.
Women who had more than 2 previously completed
consecutive unsuccessful in vitro fertilization (IVF) cy-
cles or more than 3 miscarriages were excluded from
the trial; as were women with a history of severe ovar-
ian hyperstimulation syndrome (OHSS) as defined by
Papanikolaou and colleagues [11], primary ovarian fail-
ure or being categorized as poor responders to ovarian
stimulation, or hypersensitivity or allergy to rFSH prep-
arations. Also excluded from the trial were women who
had any significant cardiovascular, pulmonary, neuro-
logic, endocrine, hepatic, or renal disease; or neoplasm
or a history of chemotherapy or radiation therapy; or
who had used clomiphene or gonadotropins within
30 days prior to enrollment.
To become eligible for inclusion in the study, partici-
pants were required to give written informed consent.
Study participants were free to discontinue at any time.
Pituitary down-regulation, ovarian stimulation,
and oocyte retrieval
Starting at approximately Cycle Day 21, eligible patients
received the gonadotropin-releasing hormone agonist
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buserelin acetate (Metrelef®, Ferring Arzneimittel GmbH,
Kiel, Germany) to down-regulate endogenous FSH, as
shown in Fig. 1.
After confirmation of down-regulation, women with
serum estradiol < 50 pg/mL and a negative pregnancy
test were randomly assigned (1:1) to receive either
Ovaleap® or Gonal-f® through an interactive voice
response system initiated by study personnel. The
randomization scheme was computer-generated and
stratified by study center using a block size of 2. Women
with ovarian cysts > 10 mm, verified by ultrasound after
down-regulation, could not be randomized to study
treatment and were excluded from the trial. Investigators
received no information about treatment allocation and
the size of the randomization blocks was not disclosed
in the protocol or to the study centers. The investigators
and embryologists were kept blinded and performed all
assessments without knowledge of treatment.
Ovaleap® (Merckle Biotec GmbH, Ulm, Germany) was
supplied in glass cartridges containing 900 IU in 1.5 mL
solution to be administered from a reusable semi-
automated pen device. Gonal-f® (Merck Serono S.p.A.,
Modugno, Italy) contained 900 IU in 1.5 mL solution to
be administered using a prefilled pen. Because the drugs
were administered using two different and unique pen
devices, a double-blind study design was not feasible.
However, a single-blind design was maintained through
the use of a “drug administrator” (eg, a physician or
nurse) who instructed the patient how to use the study
drug, but who was not involved in any study assess-
ments. The drug administrator also instructed the pa-
tient not to disclose her assigned study drug (Ovaleap®
or Gonal-f®) to the investigator and the embryologist.
Eligible patients were treated for 1 stimulation cycle
with Ovaleap® or Gonal-f® as stimulating agent using a
long GnRH agonist protocol. Patients received SC injec-
tions in fixed doses of 150 IU of Ovaleap® or Gonal-f®
daily for the first 5 days. The first dose was injected by
the drug administrator at the study center; subsequent
doses were self-administered by the patient. To achieve
adequate follicular development, doses could be ad-
justed (up or down) at the investigators’ discretion
(based on their assessment of follicle count, size, and
appearance) after Day 5 every 3 to 5 days through Day
20 in increments of 37.5 IU (but no more than 150 IU)
to a maximum of 450 IU/day, based on serum estradiol
levels and ultrasound examinations.
Women who had at least 3 follicles with a mean diam-
eter of 17 mm, as assessed using transvaginal ultrasound,
and estradiol levels below 5500 pg/mL then received hu-
man chorionic gonadotropin (hCG; Ovitrelle®, Merck
Serono S.p.A., Modugno, Italy) to induce follicular mat-
uration and trigger ovulation.
Oocyte retrieval took place 34 to 37 h after hCG ad-
ministration. Luteal support was provided after oocyte
retrieval at the investigators’ discretion. Evaluation of
biochemical pregnancy (defined as a positive β-hCG
test) occurred 16 to 19 days after oocyte retrieval, while
evaluation of clinical pregnancy (defined as gestational
sac with fetal heart activity) occurred 5 to 7 weeks
post-oocyte retrieval.
Outcome measures
The primary endpoint was the number of oocytes re-
trieved. Secondary endpoints included total r-hFSH
dose, number of patients needing dose adaptations, dur-
ation of dosing, number of follicles, serum estradiol con-
centration, and endometrial thickness prior to dose
adaptation (Stimulation Day 6) and on the day of hCG
injection, and cancellation rate prior to oocyte retrieval.
After oocyte retrieval and fertilization, fertilization out-
come was assessed and recorded using the following cat-
egories: without pronucleus (PN), 1 PN, 2 PN, 3 or more
PN, and other. The quality of all 2 PN oocytes (zygotes)
was then evaluated using the zygote scoring system of
Scott et al. [12]. Number of embryos obtained, trans-
ferred, and cryopreserved; biochemical and clinical preg-
nancy rate; and take-home baby rate (defined as the
percentage of randomized patients with live births) were
also assessed. Patients with clinical pregnancies were
followed until birth for any complications during preg-
nancy and delivery.
Safety and tolerability were monitored by recording
treatment-emergent adverse events (TEAEs), including
OHSS; results of laboratory tests, including assessments
of hematology, clinical chemistry, hormone levels, and
immunogenicity (antibody levels); electrocardiograms
(ECGs); vital signs; body weight measurements; local
Fig. 1 Study design. GnRHa, gonadotropin-releasing hormone agonist; r-hFSH, recombinant human follicle stimulating hormone; hCG, human
chorionic gonadotropin; ẞ-hCG, beta-human chorionic gonadotropin; w, weeks; d, days; hrs, hours
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and overall tolerability, physical examinations, and pa-
tient satisfaction with the pen device.
Anti-FSH antibodies were assessed in all randomized
patients at 3 time points: baseline, day of oocyte retrieval,
and 3 months after the last administration of Ovaleap® or
Gonal-f®. Serum samples were assessed for the presence
of anti-FSH antibodies using validated assays at 2 cen-
tral laboratories. The initial anti-drug antibodies assay
was revised for sensitive detection of anti-Ovaleap® and
anti-N-glycolylneuraminic acid (anti-Neu5Gc) antibodies
in human serum samples. The sensitivity of the new assay
increased by about 10-fold.
Patients evaluated injection-site pain after each injec-
tion using a numerical scale ranging from 0 (no pain at
all) to 10 (the most severe pain). They also recorded
the presence and intensity of injection-site reactions,
such as redness, bruising, swelling, burning, or skin ir-
ritation. In addition, patients rated the convenience of
the pen using a 3-point rating scale, as well as their sat-
isfaction with the administration of r-hFSH using a pen
by completing a questionnaire based on that used by
Somkuti et al. [13].
Statistical analysis
The aim of the study was to evaluate equivalence of
Ovaleap® compared with Gonal-f® with respect to the
primary efficacy endpoint, the number of oocytes re-
trieved. A sample size of 124 patients per group was
determined to be necessary to achieve 90 % power (a
two-sided level of α = 0.05) for rejecting the null
hypothesis that Ovaleap® is different from Gonal-f®.
Ovaleap® was to be considered clinically equivalent to
Gonal-f® if the difference in the mean number of oo-
cytes retrieved between the 2 groups was ≤ 3 (primary
endpoint). The prespecified margin of 3 oocytes has been
used in previous equivalence trials of Gonal-f® [14, 15].
The anticipated difference in the expected mean num-
ber of oocytes was ≤ 0.5 with a common standard devi-
ation of 6 oocytes. Assuming that about 10 % of
patients would not be eligible for the analysis of the pri-
mary endpoint due to protocol violations or dropouts,
140 patients per treatment group were to be included
in the trial.
A zero-inflated Poisson regression (ZIP) was used to
assess the primary endpoint, with treatment and country
as fixed factors and age as a covariate. The primary end-
point was evaluated in all randomized patients (intent-
to-treat [ITT] population) as well as in those who did
not have any major protocol violations (according-to-
protocol [ATP] population). The safety analysis included
all randomized patients who received at least 1 dose of
r-hFSH (Ovaleap® or Gonal-f®). A stratified post-hoc ana-
lysis of clinical and ongoing pregnancy rates by baseline
and post-baseline characteristics was also performed.
Secondary endpoints, presented only for the ITT
population, were assessed using descriptive statistics
(eg, mean ± SD, median, and range). Stratified odds ra-
tios and related P-values on secondary endpoints were
calculated using Mantel-Haenszel tests. Since resultant
P-values were regarded as supportive only, no adjust-
ment for multiple testing was made.
Results
Subject disposition and baseline characteristics
Of the 398 women screened, 299 were randomized (ITT
population) to receive either Ovaleap® (n = 153) or
Gonal-f® (n = 146), as shown in Fig. 2. The number of
patients randomized per study center ranged from 1 to 2
at study centers in Belgium, 6 to 17 at study centers in
the Czech Republic, 3 to 16 at study centers in
Germany, 36 to 41 at study centers in Hungary, and 18
to 30 at study centers in Poland (Table 1). The ATP
population (n = 297) differed only slightly from the ITT
population in that 2 patients (1 per group) in the ITT
population underwent dose adaptation during the fixed-
dose period, which was considered a major protocol viola-
tion. Demographic and baseline characteristics—including
age, weight, BMI, smoking, and alcohol consumption, as
well as reasons for, and durations of, infertility—were
comparable between treatment groups (Table 2).
Efficacy outcomes
Number of oocytes retrieved
At least 1 oocyte was harvested in 295/299 patients in
the ITT population (152/153 with Ovaleap® and 143/146
with Gonal-f®). The cancellation rate prior to oocyte re-
trieval thus was 0.7 % (n = 1) and 2.1 % (n = 3), respect-
ively. In the ATP population, at least 1 oocyte was
harvested in 294/297 patients, making the cancellation
rate 0.7 % and 1.4 % in the Ovaleap® and Gonal-f®
groups, respectively.
The number of oocytes retrieved per patient was
similar in both groups. Using an imputation value of
zero for patients without oocyte retrieval, Ovaleap®-
treated patients had 12.2 ± 6.8 (SD) (median [range]: 11
[0 to 36]) oocytes retrieved vs 11.9 ± 6.9 (median
[range]: 12 [0 to 44]) in Gonal-f®–treated patients.
Without applying any imputation, oocyte retrievals
were nearly identical (12.2 ± 6.7 vs 12.1 ± 6.7, with
Ovaleap® and Gonal-f®, respectively). The ZIP regres-
sion analysis revealed a mean difference of 0.03 oocytes
between treatment groups (Ovaleap® minus Gonal-f®)
(95 % CI: –0.76-0.82), which was well within the pre-
specified equivalence range, thus demonstrating the
equivalence of Ovaleap® and Gonal-f®. Results were
similar in the ATP population (12.2 ± 6.8 oocytes with
Ovaleap® vs 12.0 ± 6.8 oocytes with Gonal-f® [imputed
values]), also demonstrating equivalence.
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Seventy-five patients in the Ovaleap® group and 61 pa-
tients in the Gonal-f® group completed the study without
dose adaptation. The mean number of oocytes retrieved
in these patients was similar between treatment groups
(11.9 vs 12.5). According to the ZIP regression model,
age and country had a statistically significant effect on
oocyte number (P < 0.001) but study treatment did not
(P = 0.940).
r-hFSH dose and duration
Overall, treatment groups were similar with respect to
secondary endpoints. Results in the ITT population
(described below) were similar to the ATP population
(not shown).
The mean total dose of r-hFSH (±SD) was slightly but
not significantly lower in the Ovaleap® group compared
to the Gonal-f® group (1536 [±496] IU vs 1614 [±485]
IU, respectively) (Table 3). The proportions of patients
requiring dose adaptations were 51.0 % in the Ovaleap®
group and 58.2 % in the Gonal-f® group. In addition, the
mean number of days of r-hFSH stimulation was similar
in the Ovaleap® group compared with the Gonal-f®
group: 9.3 days vs 9.7 days, respectively, with most
Table 1 Distribution of patients by country (ITT population)
Country Ovaleap®
(n = 153)
Gonal-f®
(n = 146)
Total
(N = 299)
Belgium + Germanya 35 30 65
Czech Republic 30 28 58
Hungary 39 38 77
Poland 49 50 99
a3 patients were randomized in Belgium: 1 to Gonal-f® and 2 to Ovaleap®
Fig. 2 Patient disposition. ITT, intent-to-treat. *Subjects could be excluded for multiple reasons. The 2 protocol violations post-allocation involved
patients whose dosing was adapted during the fixed-dose phase
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patients receiving stimulation for 8 to 11 days: 123
(80.4 %) with Ovaleap®, 121 (82.9 %) with Gonal-f®.
Follicular, hormonal, and endometrial characteristics
There were no clinically relevant differences in the dis-
tribution of follicle size at the end of the fixed-dose
phase between groups. Both groups had similar sub-
stantial increases in the number of follicles > 14 mm at
the end of the dose-adaptation phase (Fig. 3). At the
end of the fixed-dose phase, the mean number of folli-
cles > 14 mm was 1.0 in the Ovaleap® group and 0.4 in
the Gonal-f® group. By the day of hCG administration,
the number had increased to 10.8 in the Ovaleap®
group and 10.5 in the Gonal-f® group. However, serum
estradiol levels were variable. Mean estradiol levels
were significantly higher with Ovaleap® than with
Gonal-f® at the end of the fixed-dose phase (650.2 vs
516.3 pg/mL; P = 0.009) but had increased to similar
levels by the day of hCG administration (2744.3 vs
2598.5 pg/mL; P = 0.52).
In both groups, administration of r-hFSH was accom-
panied by a 3-fold increase in mean endometrial thick-
ness from 3.7 mm at the start of fixed-dose r-hFSH to
10.9 mm on the day of hCG administration that was
identical for both groups (Fig. 4). At the end of the
fixed-dose phase, endometrial thickness was similar be-
tween groups (8.2 mm with Ovaleap® vs 8.0 mm with
Gonal-f®).
Embryo characteristics and numbers
The morphology of the retrieved 2 PN oocytes was
graded as Z1 (best quality) to Z4 (worst quality). Ap-
proximately 20 % of the 1689 oocytes were graded as Z1,
40 % as Z2, 30 % as Z3, and 10 % as Z4, with a similar
distribution between the treatment groups (ITT popula-
tion, Table 4).
The median numbers of embryos obtained and
transferred were similar between groups. A median of
3 embryos was obtained per patient in both treatment
groups, with a range of 0 to 20 in the Ovaleap®-
treated group and a range of 0 to 22 in the Gonal-f®
group. A median of 2 embryos (range 0 to 3) was
transferred per patient in both treatment groups. In
24 patients (12 in each group), embryo transfers were
not performed.
Pregnancies
There were no significant differences in clinical and bio-
chemical pregnancy rates between the Ovaleap® and the
Gonal-f® groups (Table 5).
Fifty-eight patients (37.9 %) in the Ovaleap® group had
biochemical pregnancies compared with 60 (41.1 %) in
the Gonal-f® group (P = 0.606). Clinical pregnancy rates
were 28.1 % (43/153) in the Ovaleap® group and 35.6 %
(52/146) in the Gonal-f® group (P = 0.172). In addition,
clinical pregnancy rates with Ovaleap® and Gonal-f® were
similar among patients who had oocytes retrieved and
similar among patients who underwent embryo transfer.
However, a post-hoc analysis revealed substantial vari-
ability in clinical pregnancy rates from country to country
(28.6 % [10/35] with Ovaleap® and 16.7 % [5/30] with
Gonal-f® in Belgium-Germany, 30.0 % [9/30] with Ovaleap®
and 39.3 % [11/28] with Gonal-f® in the Czech Republic,
35.9 % [14/39] with Ovaleap® and 44.7 % [17/38] with
Gonal-f® in Hungary, and 20.4 % [10/49] with Ovaleap®
and 38.0 % [19/50] with Gonal-f® in Poland) and from cen-
ter to center. An additional 4 patients who did not achieve
Table 2 Baseline demographics and patient characteristics
(ITT population)
Characteristic Ovaleap®
(n = 153)
Gonal-f®
(n = 146)
Age, years, mean (SD) 31.6 (3.1) 31.7 (3.2)
Age, n (%)
< 30 years 35 (22.9) 36 (24.7)
30 to 34 years 93 (60.8) 75 (51.4)
> 34 years 25 (16.3) 35 (24.0)
Weight, kg, mean (SD) 63.8 (10.2) 63.1 (9.2)
BMI, kg/m2, mean (SD) 22.8 (2.9) 22.6 (2.9)
Smoker, n (%) 18 (11.8) 19 (13.0)
Alcohol consumption, n (%) 33 (21.6) 23 (15.8)
Duration of infertility, in months at baseline,
mean (SD)
43.6 (26.2) 46.6 (29.0)
Causes of infertilitya, n (%)
Male factor 86 (56.2) 77 (52.7)
Idiopathic 39 (25.5) 41 (28.1)
Tubal factor 26 (17.0) 30 (20.5)
Endometriosis 10 (6.5) 10 (6.8)
Other 6 (3.9) 10 (6.8)
Pregnancy history, n (%)
Previous pregnancy 45 (29.4) 51 (34.9)
Previous miscarriage 22 (14.4) 35 (24.0)
Previous still birth 4 (2.6) 1 (0.7)
Previous live birth 27 (17.6) 20 (13.7)
Total ovarian volume, mL
Mean (SD) 19.0 (50.7) 15.5 (11.8)
Median 12.0 12.6
Basal antral follicles ≥ 5 mm, mean (SD) n = 153 n = 145
Right ovary 5.3 (3.4) 5.2 (4.3)
Left ovary 5.0 (3.2) 4.8 (4.3)
Basal FSH levels, mU/mL, mean (SD) 7.0 (1.6) 7.3 (2.3)
ITT intent-to-treat, SD standard deviation, BMI body mass index,
FSH follicle-stimulating hormone
aMultiple causes per patient are possible
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biochemical pregnancy after embryo transfer received their
frozen embryos obtained during this study and became
pregnant. Thus, a total of 99 pregnancies were recorded
(46 Ovaleap® and 53 Gonal-f®).
Rates of ongoing pregnancies, defined by ultra-
sound (or by birth or stillbirth if ultrasound informa-
tion was missing), were 27.5 % for patients treated
with Ovaleap® and 33.6 % with Gonal-f® (Table 5). A
post-hoc analysis revealed variability in ongoing preg-
nancy rates from country to country (25.7 % [9/35]
with Ovaleap® and 13.3 % [4/30] with Gonal-f® in
Belgium-Germany, 23.3 % [7/30] with Ovaleap® and
32.1 % [9/28] with Gonal-f® in the Czech Republic,
35.9 % [14/39] with Ovaleap® and 44.7 % [17/38]
with Gonal-f® in Hungary, and 24.5 % [12/49] with
Ovaleap® and 38.0 % [19/50] with Gonal-f® in Poland)
and from center to center as seen in the post-hoc
analysis of clinical pregnancy rates.
The incidences of pregnancy loss were similar in both
groups, occurring in 8/153 (5.2 %) of Ovaleap®-treated
patients and 9/146 (6.2 %) of Gonal-f®–treated patients.
Ectopic pregnancy occurred in 2 Ovaleap®-treated pa-
tients (1.3 %) and in 1 Gonal-f®–treated patient (0.7 %);
none were assessed by the investigator as related to
study medication. Three patients had other complica-
tions, including Down’s syndrome (Ovaleap® group
[with subsequent clinical abortion]), premature deliv-
ery of triplets (Gonal-f® group), and epilepsia parox-
ysm (Gonal-f® group).
Live births and take-home baby rates
Approximately 90 % of clinically pregnant patients went
on to have a live birth, 89.1 % (41/46) in the Ovaleap®
group and 88.7 % (47/53) in the Gonal-f® group. Take-
home baby rates, defined as the percentage of random-
ized patients with live births, were 26.8 % (41/153) with
Fig. 3 Follicle size after fixed-dose phase (Stimulation Day 6) and follicles >14 mm after dose adaptation (Day of hCG Administration) (ITT population).
In Ovaleap® group, n = 153 at both time points; in Gonal-f® group, n = 146 on Day 6 and 144 on hCG day; error bars show standard deviation
Table 3 Secondary outcomes related to r-hFSH dosing (ITT population)
Characteristic Ovaleap® (n = 153) Gonal-f® (n = 146) Odds Ratio (95 % CI) P-value
Total r-hFSH dose, IU, mean (SD) 1536 (496) 1614 (485) N/A 0.065
Dose adaptation, n (%)
Total 78 (51.0) 85 (58.2) 0.75 (0.47–1.18) 0.215
Dose increase 55 (35.9) 63 (43.2) 0.74 (0.47–1.18) 0.202
Dose decrease 23 (15.0) 22 (15.1) 1.02 (0.52–1.98) 0.964
Duration of r-hFSH stimulation, days
Mean (SD) 9.3 (1.8) 9.7 (1.6) N/A 0.131
Median (range) 9 (5–16) 10 (6–16)
r-hFSH recombinant human follicle stimulating hormone, SD standard deviation, N/A not applicable
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Ovaleap® and 32.2 % (47/146) with Gonal-f® (Table 5).
Overall, a total of 111 live births occurred in the study
and were similarly distributed between the 2 treatment
groups, with 54 live babies in the Ovaleap® group and 57
live babies in the Gonal-f® group. Multiple births oc-
curred in 22 women, or 25 % of the participants who
had live births. In the Ovaleap® group, 13/41 patients
who had live births (31.7 %) had twins. There were 8 pa-
tients with twins and 1 patient with triplets in the
Gonal-f® group (9/47 live births, 19.1 %). Two babies
born prematurely to women in the Gonal-f® group died
(1 singleton, 1 of a set of triplets). One patient in the
Gonal-f® group had a still birth, and no still births oc-
curred in the Ovaleap® group.
Safety and tolerability
Overall frequencies of TEAEs were low and comparable
across treatment groups: 16.3 % (25/153) in the Ovaleap®
group and 15.1 % (22/146) in the Gonal-f® group. The
most common TEAEs were OHSS (4.6 % [7/153] in the
Ovaleap® group and 2.7 % [4/146] in the Gonal-f® group),
abdominal pain (3.3 % [5/153] Ovaleap®; 0.7 % [1/146]
Gonal-f®), and missed abortion (2.1 % [3/146] Gonal-f®)
(Table 6). Severe TEAEs were reported in 7 patients
(3 Ovaleap®, 4 Gonal-f®) and included 2 events of
OHSS (1 per treatment group).
OHSS was reported in 11 patients (7 Ovaleap®
[4.6 %]; 4 Gonal-f® [2.7 %]). The difference in the fre-
quency of OHSS between groups was not statistically
significant (P = 0.542). OHSS was rated as mild in 3 pa-
tients assigned to Ovaleap® and 2 patients assigned to
Gonal-f®, moderate in 3 patients assigned to Ovaleap®
and 1 patient assigned to Gonal-f®, and severe in 1 pa-
tient in each group. No cases of life-threatening OHSS
were reported; however, OHSS led to hospitalization in
1 patient in each group. OHSS led to treatment discon-
tinuation in 1 patient in the Ovaleap® group and 2 pa-
tients in the Gonal-f® group. All cases had resolved by
the end of the study, except 1 case in which the out-
come is unknown.
Serious TEAEs occurred in 16 patients, including
abortion (2 Ovaleap®, 3 Gonal-f®), OHSS (3 Ovaleap®, 2
Gonal-f®), ectopic pregnancy (2 Ovaleap®, 1 Gonal-f®),
abdominal pain (1 each group), and antepartum
hemorrhage (Ovaleap®). Of the 17 pregnancy losses that
occurred during the study, 10 were not considered
TEAEs since they occurred > 30 days after completion of
treatment with r-hFSH.
There were no clinically relevant changes in laboratory
variables, electrocardiogram, physical examination, body
weight, or vital signs that emerged as a result of treat-
ment. Nonneutralizing antibodies toward of IgA, IgG,
and IgM classes were detected in the immunogenicity
assays but were not clinically relevant because they were
predominantly directed at motifs not present in CHO
cell-produced glycoproteins. Among the 22 patients who
showed post-dose positive findings using the revised
highly sensitive assay, 5 treated with Gonal-f® and 11
treated with Ovaleap® in the first treatment cycle had
Fig. 4 Mean (SD) endometrial thickness over the course of r-hFSH treatment (ITT population)
Table 4 Oocyte quality (ITT population)
Characteristic Ovaleap® (n = 144) Gonal-f® (n = 135)
Oocyte quality, n (%) of oocytes
Z1 (best) 188 (20.7) 164 (21.1)
Z2 337 (37.0) 305 (39.2)
Z3 278 (30.5) 227 (29.1)
Z4 (worst) 107 (11.8) 83 (10.7)
Total 2 PN oocytes 910 (100.0) 779 (100.0)
ITT intent-to-treat, PN pronucleus
Z score = zygote scoring system of Scott et al. 2000 [12]
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positive findings, which were mainly against Neu5Gc.
However, none of these positive findings showed neutral-
izing activity. No positive findings related to the IgE class
were identified.
Patient-reported outcomes
Overall, tolerability was good and comparable between
patient groups, with minimal injection-site pain and
injection-site reactions.
Patients were highly satisfied with both Ovaleap® and
Gonal-f® pen devices (Table 7); > 75 % in both groups
gave a rating of “very confident” in terms of accurate
dosing and correct injection and “very convenient” and
“very satisfied” in terms of administration. More than
70 % rated the instructional text to be “very easy” to
understand. Less than 5 % needed more than 1 explan-
ation about how to use the device.
Discussion
Our phase 3 patient-study found Ovaleap® to be equiva-
lent to Gonal-f® in the primary endpoint of the number
of oocytes retrieved in a population of infertile women
undergoing ovulation stimulation during ART, which is
the primary endpoint recommended by the EMA for tri-
als comparing Gonal-f® to biosimilar preparations. In
addition, the secondary study endpoints of follicle num-
ber and size and endometrial thickness were comparable
between groups at the end of the fixed-dose phase, and
the numbers of oocytes retrieved were similar in patients
who did not require dose adaptation, suggesting the
clear comparability of these formulations. Oocyte qual-
ity, as assessed by Z scores, was also similar between
groups, with no clinically significant differences ob-
served. The number of oocytes retrieved in patients
treated with Ovaleap® and Gonal-f® were also compar-
able to those in previous studies of Gonal-f® in infertile
patients who were treated with a long protocol and
down-regulated with a GnRH agonist [15–20].
The clinical pregnancy rate for patients associated with
Gonal-f® treatment has ranged from 23 % to 39 % in the
literature [15, 17]. The clinical pregnancy rates with em-
bryo transfer of 30.7 % for Ovaleap®-treated patients and
38.8 % for Gonal-f®–treated patients in this study both
are consistent with that range. The difference in clinical
Table 5 Pregnancy characteristics (ITT population)
Ovaleap® Gonal-f® Odds Ratio (95 % CI) P-value*
Biochemical pregnancies
All patients, n/N (%) 58/153 (37.9) 60/146 (41.1) 0.88 (0.55–1.41) 0.606
Clinical pregnancy rates, n/N (%)
All patients 43/153 (28.1) 52/146 (35.6) 0.71 (0.43–1.16) 0.172
Patients with oocyte retrieval 43/152 (28.3) 52/143 (36.4) 0.70 (0.42–1.14) 0.150
Patients with embryo transfer 43/141 (30.5) 52/134 (38.8) 0.70 (0.42–1.15) 0.163
Ongoing pregnancy rates, n/N (%)
All patients 42/153 (27.5) 49/146 (33.6) 0.76 (0.46–1.25) 0.275
Patients with oocyte retrieval 42/152 (27.6) 49/143 (34.3) 0.75 (0.45–1.23) 0.251
Patients with embryo transfer 42/141 (29.8) 49/134 (36.6) 0.74 (0.45–1.24) 0.255
Take-home baby rates, n/N (%)a
All patients 41/153 (26.8) 47/146 (32.2) 0.78 (0.47–1.29) 0.335
Patients with oocyte retrieval 41/152 (27.0) 47/143 (32.9) 0.77 (0.46–1.27) 0.310
Patients with embryo transfer 41/141 (29.1) 47/134 (35.1) 0.77 (0.46–1.28) 0.307
*Calculated using a Mantel-Haenszel test, adjusting for the country factor
aTake-home baby rate equals the percentage of patients with live births (from fresh or frozen cycles) divided by the number of randomized patients. All other
outcomes reported in this table only include pregnancies resulting from fresh cycles
Table 6 TEAEs occurring in 2 or more patients during the main
study, n (%) (Safety Population)
Symptom Ovaleap®
(n = 153)
Gonal-f®
(n = 146)
Total
(N = 299)
OHSS 7 (4.6) 4 (2.7) 11 (3.7)*
Abdominal pain 5 (3.3) 1 (0.7) 6 (2.0)
Abortion missed 0 3 (2.1) 3 (1.0)
Ectopic pregnancy 2 (1.3) 1 (0.7) 3 (1.0)**
Nasopharyngitis 1 (0.7) 2 (1.4) 3 (1.0)
Nausea 2 (1.3) 1 (0.7) 3 (1.0)
Antepartum hemorrhage 1 (0.7) 1 (0.7) 2 (0.7)
Headache 2 (1.3) 0 2 (0.7)
OHSS, ovarian hyperstimulation syndrome; TEAEs, treatment-emergent
adverse events
*P = 0.54
**P = 1.0
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pregnancy rates between groups was not statistically sig-
nificant and may be indicative of the substantial variabil-
ity in clinical pregnancy rates we observed between
study sites and countries of origin. For example, clinical
pregnancy rates were as low as 20.4 % with Ovaleap® in
Poland and as high as 35.9 % in Hungary. With Gonal-f®,
clinical pregnancy rates were as low as 16.7 % in
Belgium +Germany and as high as 44.7 % in Hungary.
Higher clinical pregnancy rates in the Gonal-f® group
were seen in the Czech Republic (42.3 % vs 36.0 %),
Hungary (46.0 % vs 36.8 %), and Poland (40.4 % vs
20.8 %). In Belgium + Germany, however, the clinical
pregnancy rate was higher in the Ovaleap® group than in
the Gonal-f® group (33.3 % vs 20.8 %). The stratified
post-hoc analysis of clinical and ongoing pregnancy rates
by baseline and post-baseline characteristics did not re-
veal any findings to explain the differences in rates
among sites and countries.
An important goal toward improving ART is to lower
the rate at which couples discontinue ART. Interviews
with couples have revealed that the emotional stress or
psychological burden involved with the treatment
process is an important factor determining the risk of
treatment discontinuation [21, 22]. Research with regard
to patient preferences during infertility treatment is
scarce; although patient preference or perceived con-
venience may drive the choice of gonadotropic agent.
For example, a recent questionnaire study conducted
in Sweden showed that patients preferred ovarian
stimulation treatments that they believed would re-
duce dose variability and were easy to use [23]. The
authors of this study speculated that patients equate
dose variability with poor quality and a greater risk of
TEAEs, such as OHSS.
In the present study, the Ovaleap® pen device re-
ceived high patient ratings in overall ease of use and
confidence in accurate dosing. Patients were able to
self-administer after only one demonstration on site.
Although the majority of patients had previous ex-
perience using the Gonal-f® pen, patients assigned to
Ovaleap® were similarly confident about the accuracy
of dosing and administration, indicating the ease of
use of the Ovaleap® pen. Taking patient convenience
into consideration, using pen devices may be an im-
portant way to help reduce the psychological stress of
fertility treatment and perhaps improve treatment
success [24].
Ovaleap® was found to have a favorable safety profile,
similar to that of Gonal-f®, with no new unexpected
safety concerns identified. OHSS was the most common
TEAE (11/153, 7.2 %), and all episodes (except in 1 pa-
tient who was lost to follow-up) resolved. The numbers
of OHSS cases were small with no statistically significant
differences between groups, and comparable to that seen
with other FSH products [11, 18, 25–27].
One potential limitation of this randomized, multi-
center, and otherwise well-designed study is that the
lack of patient blinding due to the use of the patent-
protected Gonal-f® pen device could result in bias.
However, because this study design was similar to
that of other comparative studies of ART using r-
hFSH [18, 19], this potential bias was not considered
to be a significant concern. It is also conceivable that
regional variations in laws, practices, and preferences
with regard to ART practices, which may have con-
tributed to the differences in clinical and ongoing
pregnancy rates from country to country, may have
introduced bias. In addition, the relative leanness of
the patients included in this study (mean BMI, 22 kg/m2)
should also be considered when generalizing study results
to other patient populations.
Although the primary endpoint of our study was the
number of oocytes retrieved, live birth rates might have
been a more clinically meaningful outcome to patients.
However, the number of oocytes retrieved is the primary
endpoint recommended by the European Medicines
Agency for studies evaluating the clinical comparability of
Gonal-f® and biosimilar formulations [5], and using live
Table 7 Patient satisfaction with study pen device, n (%)
Characteristic Ovaleap® (n = 151) Gonal-f® (n = 142)
Confidence about accurate dose
Very confident 123 (81.5) 112 (78.9)
Confident 28 (18.5) 30 (21.1)
Confidence about correct injection
Very confident 115 (76.2) 110 (77.5)
Confident 34 (22.5) 32 (22.5)
Not confident 1 (0.7) 0 (0)
Plainness of instructional text
Very easy 113 (74.8) 100 (70.4)
Easy 38 (25.2) 42 (29.6)
Frequency of need for explanation
of administration
Never 85 (56.3) 67 (47.2)
Once 57 (37.7) 69 (48.6)
Twice 7 (4.6) 2 (1.4)
Three times 0 (0) 1 (0.7)
Convenience of pen usage
Very convenient 117 (77.5) 107 (75.4)
Convenient 34 (22.5) 35 (24.6)
Satisfaction with administration
Very satisfied 116 (76.8) 108 (76.1)
Satisfied 35 (23.2) 34 (23.9)
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birth rates as a primary outcome would have required a
much larger, more resource-intensive study. In addition,
pregnancy rates and live birth rates are influenced by a
variety of factors beyond the scope of r-hFSH treatment
that are difficult to control. Moreover, a strong association
between the number of retrieved eggs and live birth rates
has previously been documented [10].
Conclusion
We found Ovaleap® to be a safe and effective r-hFSH for
stimulation of follicular development in infertile women
undergoing ART and similar to Gonal-f® in its safety and
efficacy. The availability of a new r-hFSH product will
give patients and providers another treatment option, in-
creasing the accessibility and possibly reducing the stress
associated with ART. An additional post-authorization,
multinational, multicenter, prospective, observational co-
hort study will further evaluate the use of Ovaleap® in
patients seeking treatment for infertility [25].
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